Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Merck, Incyte Double Down On Keytruda/Epacadostat Collaboration

Executive Summary

Expansion of 2015 development partnership adds lung and bladder cancer as well as renal and head-and-neck carcinoma to trials of the two immuno-oncology drugs. Jazz licenses Japanese rights to two of its commercial products to Nippon Shinyaku.

Advertisement

Related Content

BMS's Early Oncology Head On Novel IO Approaches & Disruptions
Incyte Eyes Big Phase III IDO Expansion, NewLink Plans First Pivotal Trial
1Q Pharma Results Preview: Merck, Pfizer, Gilead, Novo Nordisk, Shire, Allergan, Teva
Fosun On Course To Full Indian Clearance For Gland Buyout
Vanda's Licenses CFTR Modulators From UCSF, But Not For Cystic Fibrosis
Avillion Has Faith In Merck's Ablynx-Rejected Psoriasis Drug
Astellas Offloads Japan Product Basket To Private Equity Group
Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation
Jazz Veno-Occlusive Disease Drug Defitelio OK'd
Incyte and Merck Push I/O Drug Forward

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098495

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel